Literature DB >> 10637586

The targets of the lytic antibody response against Trypanosoma cruzi.

G M Krautz1, J C Kissinger, A U Krettli.   

Abstract

Trypanosoma cruzi trypomastigotes, but not epimastigotes, are normally resistant to the lytic effects of complement from vertebrate hosts susceptible to infection. This resistance facilitates parasite survival and infectivity. During the course of chronic infections, however, the vertebrate hosts produce antibodies that render the trypomastigotes sensitive to lysis, primarily via the alternative complement cascade and amplified by the classical pathway. Here, Greice Krautz, Jessica Kissinger and Antoniana Krettli summarize research on lytic antibodies, and on their respective target(s) on the T. cruzi surface. These targets are useful in tests aimed at the diagnosis of chronic Chagas disease for control of cure after specific treatment and for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10637586     DOI: 10.1016/s0169-4758(99)01581-1

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  24 in total

1.  Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.

Authors:  Silvia I Cazorla; Pablo D Becker; Fernanda M Frank; Thomas Ebensen; María J Sartori; Ricardo S Corral; Emilio L Malchiodi; Carlos A Guzmán
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

2.  Transfection of Trypanosoma cruzi with host CD40 ligand results in improved control of parasite infection.

Authors:  Mustapha Chamekh; Vincent Vercruysse; Mohammed Habib; Maxime Lorent; Michel Goldman; Abdelmounaïm Allaoui; Bernard Vray
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.

Authors:  Meagan A Barry; Qian Wang; Kathryn M Jones; Michael J Heffernan; Munir H Buhaya; Coreen M Beaumier; Brian P Keegan; Bin Zhan; Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

Review 4.  Oxidative stress implications for therapeutic vaccine development against Chagas disease.

Authors:  Subhadip Choudhuri; Lizette Rios; Juan Carlos Vázquez-Chagoyán; Nisha Jain Garg
Journal:  Expert Rev Vaccines       Date:  2021-08-30       Impact factor: 5.217

5.  Antiangiogenic and antitumor effects of Trypanosoma cruzi Calreticulin.

Authors:  Nandy C López; Carolina Valck; Galia Ramírez; Margarita Rodríguez; Carolina Ribeiro; Juana Orellana; Ismael Maldonado; Adriana Albini; Daniel Anacona; David Lemus; Lorena Aguilar; Wilhelm Schwaeble; Arturo Ferreira
Journal:  PLoS Negl Trop Dis       Date:  2010-07-06

6.  Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10

Review 7.  Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease.

Authors:  Fabiana S Machado; Walderez O Dutra; Lisia Esper; Kenneth J Gollob; Mauro M Teixeira; Stephen M Factor; Louis M Weiss; Fnu Nagajyothi; Herbert B Tanowitz; Nisha J Garg
Journal:  Semin Immunopathol       Date:  2012-10-18       Impact factor: 9.623

8.  Interspecific variation in redox status regulation and immune defence in five bat species: the role of ectoparasites.

Authors:  T M Lilley; J Stauffer; M Kanerva; T Eeva
Journal:  Oecologia       Date:  2014-05-18       Impact factor: 3.225

Review 9.  Nano-Medicines a Hope for Chagas Disease!

Authors:  Satabdi Datta Choudhury
Journal:  Front Mol Biosci       Date:  2021-06-01

10.  Specific humoral and cellular immunity induced by Trypanosoma cruzi DNA immunization in a canine model.

Authors:  Minerva Arce-Fonseca; Martha A Ballinas-Verdugo; Emma R Abreu Zenteno; Davinia Suárez-Flores; Silvia C Carrillo-Sánchez; Ricardo Alejandre-Aguilar; José Luis Rosales-Encina; Pedro A Reyes; Olivia Rodríguez-Morales
Journal:  Vet Res       Date:  2013-03-11       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.